ProQR Therapeutics NV (PRQR)
3.64
+0.01
(+0.28%)
USD |
NASDAQ |
Nov 05, 14:29
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 297.32M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 200.0% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 17.79 |
Price to Book Value | 8.443 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.1351 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 97.50% |
Profile
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. |
URL | https://www.proqr.com |
Investor Relations URL | https://www.proqr.com/investors-and-media |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | Nov. 07, 2024 (est.) |
Last Earnings Release | Aug. 08, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. |
URL | https://www.proqr.com |
Investor Relations URL | https://www.proqr.com/investors-and-media |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | Nov. 07, 2024 (est.) |
Last Earnings Release | Aug. 08, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |